KYTX
Kyverna Therapeutics, Inc. Common Stock
NASDAQ: KYTX · HEALTHCARE · BIOTECHNOLOGY
$9.47
+2.82% today
Updated 2026-05-06
Market cap
$557.48M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.64
Dividend yield
—
52W range
$2 – $14
Volume
0.9M
Kyverna Therapeutics, Inc. Common Stock (KYTX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+6.4%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+7.8%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-5.9%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-6.1%
2025-11-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-27 | $-0.80 | +6.8% | $8.03 | $7.58 | -5.6% |
| 2025-11-13 | $-0.85 | +16.7% | $7.33 | $6.88 | -6.1% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.86 | $-0.80 | +6.8% | — | — |
| 2025-09-30 | $-1.02 | $-0.85 | +16.7% | — | — |
| 2025-06-30 | $-1.02 | $-0.97 | +4.9% | — | — |
| 2025-03-31 | $-1.00 | $-1.03 | -2.7% | — | — |
| 2024-12-31 | $-0.95 | $-0.87 | +8.7% | $2.02M | — |
| 2024-09-30 | $-0.84 | $-0.80 | +4.8% | — | — |
| 2024-06-30 | $-0.78 | $-0.67 | +14.1% | — | — |
| 2024-03-31 | $-0.84 | $-1.12 | -33.3% | — | — |
| 2023-12-31 | $-3.23 | $-26.86 | -731.6% | — | — |
Frequently asked questions
Has Kyverna Therapeutics, Inc. Common Stock beaten earnings estimates?
Kyverna Therapeutics, Inc. Common Stock has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +6.4% over the last 4 quarters.
How does KYTX stock react to earnings?
KYTX stock has moved an average of -5.9% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.